about
Pathways and therapeutic targets in melanomaIn silico investigation of potential SRC kinase ligands from traditional Chinese medicineA phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignanciesCombined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer.Therapy for metastatic melanoma: the past, present, and future.A review of novel therapies for melanoma.GNAQ mutation in a patient with metastatic mucosal melanoma.Driver mutations in melanoma: lessons learned from bench-to-bedside studiesResistance to c-Kit inhibitors in melanoma: insights for future therapiesPredictive biomarkers for dasatinib treatment in melanoma.Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanomaIn vitro studies of dasatinib, its targets and predictors of sensitivity.Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanomaTargeted agents for the treatment of metastatic melanoma.Targeting drivers of melanoma with synthetic small molecules and phytochemicals.Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.Proteolysis of EphA2 Converts It from a Tumor Suppressor to an OncoproteinDrug targets and predictive biomarkers in the management of metastatic melanoma.Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN statusActivation of Src, Fyn and Yes non-receptor tyrosine kinases in keratinocytes expressing human papillomavirus (HPV) type 16 E7 oncoprotein.LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanomaSRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma.Bosutinib Therapy Ameliorates Lung Inflammation and Fibrosis in Experimental Silicosis.BRAF and beyond: Tailoring strategies for the individual melanoma patientMelanoma update: diagnostic and prognostic factors that can effectively shape and personalize management.Current status of primary malignant melanoma of the esophagus: clinical features, pathology, management and prognosis.Profile of ipilimumab and its role in the treatment of metastatic melanoma.A potential role for nilotinib in KIT-mutated melanoma.Therapeutic targeting of c-KIT in cancer.Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization.Update on the targeted therapy of melanoma.Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring.Targets, structures, and recent approaches in malignant melanoma chemotherapy.New drug targets in metastatic melanoma.The potential role of sunitinib targeting melanomas.Melanoma mutagenesis and aberrant cell signaling.Therapeutic targeting of EPH receptors and their ligands.
P2860
Q26865736-3ACEA9B7-B272-4A11-93DB-AE06EFC5AF98Q28481644-C2B52CF3-1E9C-4A3A-A568-3B1438DD031CQ33404541-9073B2CC-7F57-4CA7-9528-771302575EA0Q33572971-F7B3447C-85B0-449D-9563-43E2612AA275Q34100838-08C5C5F2-10F5-4F76-BFA5-193FD4EA78CDQ34183225-CE31AB9F-A651-4984-9B31-623F73CF3AA7Q34424764-B9818CAC-DCBC-4ECD-A999-BE8835EAD1CEQ34467908-CD98AB72-CE45-48AA-9277-09AEC3BB37A3Q34639532-A0194519-7B30-4C46-A1E9-9477A0ED48CEQ34667532-02039097-F09E-4FFB-8620-6810EFCC4777Q34781153-FF3F93A6-A26E-44F2-BB2A-25691F1B2ABDQ35063621-F646A2CF-B340-4917-A613-17442E828709Q35093281-B1C4ACC0-DA4C-41CB-BBB7-E06A0217DF28Q35607192-F96FAEE6-ED16-4DE6-8E69-7470CAB41F39Q35653813-94B7A89B-AE15-4BD1-A206-00E71EB4BB59Q35822194-5FD913D3-9B63-4C98-A0D2-F360A8464FC4Q36141097-2B11A7F7-2431-491E-8C14-C4C2D306755CQ36260662-429504E5-9AE1-4726-8033-4185CBE1E9A2Q36380708-80E7010F-2A61-42AB-A1A6-B3A61ED62893Q36441552-A71A5678-B9D5-4F46-A4AA-7887708AEAFEQ36560775-23262F69-975E-48AA-8A6D-24CFAC4E1EB8Q36718672-FA6CB620-88B4-47CC-ADA0-8760EEF2802BQ36865568-50EA6A99-D874-44C9-8DC5-BF526D027833Q37509699-C3A94648-57F1-4F4A-A337-1C39B7F208B4Q37698857-1254D6A7-34D8-4349-9172-413E88D84B53Q37699569-25D0137A-B0F4-4684-AB2C-32233FAE19D1Q37702515-0E6CD35C-3482-4B6C-AFBB-09ABF9B42224Q37886997-C52E13ED-4CE2-4E55-A0E6-4F821D3805E1Q37952081-F9B69702-99A3-438E-86EA-C75672D3FE8DQ37977920-461B0805-C109-4891-B973-9DC424F5FE4EQ38002439-B5DD93E8-9F5D-4E90-AAE8-74ECCF863D5DQ38057806-F73A4CDC-049E-48A8-BC00-AE5E66B7BFA9Q38067464-DF6210B4-8120-48FA-B0B8-ED4C47D965DDQ38082713-FEF3B1A7-239D-4645-8917-05D92C4C7AD4Q38091649-FE1A6EB0-23B5-4B3F-8242-16DB4472203FQ38129832-769098A0-CAA1-44CF-92E5-46AB20B23F20Q38136595-CDB363CF-A21C-4011-9062-0AE7BADF4290Q38139560-5192C658-C9BD-4BAC-B10D-81C641141FFBQ38146707-08E7B31C-C8B1-468C-9441-AA2891C94A75Q38174793-F3E7D740-96E0-4921-A641-E90111ADE677
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A phase 2 trial of dasatinib in advanced melanoma.
@en
type
label
A phase 2 trial of dasatinib in advanced melanoma.
@en
prefLabel
A phase 2 trial of dasatinib in advanced melanoma.
@en
P2093
P2860
P356
P1433
P1476
A phase 2 trial of dasatinib in advanced melanoma.
@en
P2093
Annette Molinaro
Arkadiuz Z Dudek
Carrie McCann
Harriet M Kluger
Jean Ritacco
Lucia B Jilaveanu
Nadine Southard
P2860
P304
P356
10.1002/CNCR.25766
P407
P50
P577
2010-11-29T00:00:00Z